pegzilarginase: clinical use

Prescribing considerations

• Initiation and supervision require a physician experienced in inherited metabolic disease.
• Continue individualised dietary, amino-acid and pharmacological disease management where indicated.
• Give initial administrations under medical observation and assess hypersensitivity risk before considering home administration.
• Clinical evidence is limited by the rarity of the condition; extrapolation is uncertain in older patients with longstanding motor impairment and some diet-controlled populations.
• The product is subject to additional monitoring and is authorised under exceptional circumstances.

Contraindications and cautions

• Severe hypersensitivity to pegzilarginase or any formulation excipient.

Monitoring

• Obtain and follow plasma arginine using validated sampling procedures; tell the laboratory that the patient receives an arginine-metabolising enzyme.
• Monitor for hypersensitivity during administration and remain alert for reactions later in treatment.
• Record the product name and batch number for biological-medicine traceability.
• Monitor overall metabolic, nutritional and neurological status as part of individualised disease management.

Clinical pharmacology

Pegzilarginase is a cobalt-substituted recombinant human arginase 1 conjugated to methoxypolyethylene glycol. It replaces deficient arginase activity, reducing plasma arginine by converting it to urea and ornithine; it does not directly target raised ammonia.

Formulation and product differences

• Supplied as a clear to slightly opalescent, colourless to slightly yellow or pink solution in single-use vials.
• Intravenous administration requires dilution with sodium chloride solution; subcutaneous administration uses the undiluted solution.
• Different vial fill volumes are available, although not all presentations may be marketed.
• The formulation is essentially sodium-free and potassium-free.

Injection

Route: Parenteral

Strengths: 5 mg/mL